Revolution Medicines stock jumps on Merck buyout buzz and an FDA breakthrough tag — what to watch Monday
New York, January 10, 2026, 09:47 EST — Market closed Revolution Medicines shares jumped 10.7% to close at $118.64 on Friday, hitting a session high of $125.79 amid merger rumors. The Financial Times reported that Merck is negotiating a potential $28 billion to $32 billion acquisition of the biotech. (Financial Times) The timing matters. A deal with Revolution would give Merck a new oncology boost as patents on its top-selling cancer drug Keytruda expire later this decade. This would mark the largest pharma acquisition since Pfizer’s buyout of Seagen. (Reuters) The stock swung wildly on conflicting reports, including another round